Natural killer (NK) cell-based immunotherapies are attracting increasing interest in the field
of cancer treatment. Early clinical trials have shown promising outcomes, alongside …

A proportion of patients with lung cancer experience long-term clinical benefit with immune
checkpoint inhibitors (ICIs). However, most patients develop disease progression during …

Resistance to cancer therapies has been a commonly observed phenomenon in clinical
practice, which is one of the major causes of treatment failure and poor patient survival. The …

Background Novel immunotherapy combination therapies have improved outcomes for
patients with hepatocellular carcinoma (HCC), but responses are limited to a subset of …

Cancer immunotherapy is the great breakthrough in cancer treatment as it displayed
prolonged progression-free survival over conventional therapies, yet, to date, in only a …

Cancer poses a significant global health burden, necessitating the widespread use of
chemotherapy and radiotherapy as conventional frontline interventions. Although targeted …

Over the past few decades, cellular senescence has been identified in cancer patients
undergoing chemotherapy and radiotherapy. Senescent cells are generally characterized by …

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for
various cancer types. Multiple single or combinations of ICB treatments have been approved …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

Solid tumours display a limited response to immunotherapies. By contrast, haematological
malignancies exhibit significantly higher response rates to immunotherapies as compared …